Lennox Gastaut Syndrome (LGS)
6
0
0
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
16.7%
1 terminated out of 6 trials
50.0%
-36.5% vs benchmark
33%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Sleep-Driven Adaptive Neuromodulation in Lennox-Gastaut Syndrome
EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment
The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial
Clinical Utility of Reduced EEG Home Monitoring in Fenfluramine Titration for Dravet and LGS
A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome